


# S1. Tandem mass spectrum and corresponding iTRAQ reporter ions.

A



B




Fig 1. TsMHCII is decreased in PTCs with BRAFV600E mutation.







Fig 2. Constitutive activation of BRAF-MAPK pathway down-regulated tsmHCII expression in PTC.




S2. TsMHCII expression in PTC was downregulated by BRAFV600E at the transcriptional level.




S3. BRAFV600E-upregulated TGF- $\beta$ 1 made a impact on tsMHCII expression.


A




B




C



D





E






S4. TGF-β1 mediates downregulation of tsMHCII in BRAFV600E PTC cells via SMAD3.



TGFβ1  
Pathway  
Inhibition

Fig 3. BRAFV600E downregulated tsMHCII expression through TGF-β1/SMAD3 pathway.



## S5. TIMER web tool analysis reveals the mRNA expression of tsMHCII in various tumor types.






Fig 4. TsMHCII increased elimination effect of immune system in vitro and was correlated with good prognosis.











Fig 5. PLX4032 combined with anti-PD-1 treatment offers durable therapeutic response.

Where is the siCIITA alone sample?



Add labels to your X-axis

S6. Representative HE staining in mouse liver (left) and kidney (right) specimens.

